{
  "company_id": "jnj",
  "company_name": "Johnson & Johnson",
  "generated_at": "2026-02-04T10:56:25Z",
  "kpis": {
    "assets_total": 41,
    "assets_with_trials": 11,
    "trials_total": 258
  },
  "top_assets": [
    {
      "asset_id": 45,
      "asset_name": "ypertension75mg",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 56,
      "asset_name": "intravesical delivery system",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 30,
      "asset_name": "Hemolytic Anemia",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 38,
      "asset_name": "Gravis Pediatrics",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 39,
      "asset_name": "Disorder",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 14,
      "asset_name": "(ORIGAMI-2)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 23,
      "asset_name": "(MajesTEC-4)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 25,
      "asset_name": "TREMFYA",
      "highest_stage": "Phase 3",
      "linked_trials_count": 23,
      "indications": [
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 5,
      "asset_name": "RYBREVANT",
      "highest_stage": "Phase 3",
      "linked_trials_count": 22,
      "indications": [
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 10,
      "asset_name": "ERLEADA",
      "highest_stage": "Phase 3",
      "linked_trials_count": 20,
      "indications": [
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 57,
      "asset_name": "nipocalimab",
      "highest_stage": "Phase 3",
      "linked_trials_count": 10,
      "indications": [
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 19,
      "asset_name": "bleximenib",
      "highest_stage": "Phase 3",
      "linked_trials_count": 4,
      "indications": [
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 37,
      "asset_name": "SPRAVATO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 1,
      "indications": [
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 12,
      "asset_name": "TALVEY + TECVAYLI",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 43,
      "asset_name": "SIRTURO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 62,
      "asset_name": "Leprosy",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 22,
      "asset_name": "JNJ-7446",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 28,
      "asset_name": "JNJ-4804 Co-antibody",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 21,
      "asset_name": "JNJ-4681",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 20,
      "asset_name": "JNJ-2175",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 60,
      "asset_name": "JNJ-1887 sCD59",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 33,
      "asset_name": "ITI-1284",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 1,
      "asset_name": "INLEXZO (gemcitabine",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 9,
      "asset_name": "Bleximenib",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 55,
      "asset_name": "autoleucel",
      "highest_stage": "Phase 2",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-na\u00efve",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        }
      ]
    }
  ],
  "recent_changes": [
    {
      "event_type": "trials_ingested",
      "created_at": "2026-02-04 10:56:19.054685",
      "occurred_at": "2026-02-04 10:56:19.054685",
      "payload": {
        "trials_seen": 258,
        "inserted": 62,
        "updated": 196,
        "status_changed": 0,
        "bad_aliases": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:56:06.740648",
      "occurred_at": "2026-02-04 10:56:06.740648",
      "payload": {
        "nct_id": "NCT04883619",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:56:06.729502",
      "occurred_at": "2026-02-04 10:56:06.729502",
      "payload": {
        "nct_id": "NCT06533098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:56:06.718057",
      "occurred_at": "2026-02-04 10:56:06.718057",
      "payload": {
        "nct_id": "NCT05379634",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:56:06.694639",
      "occurred_at": "2026-02-04 10:56:06.694639",
      "payload": {
        "nct_id": "NCT05327114",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:56:06.681999",
      "occurred_at": "2026-02-04 10:56:06.681999",
      "payload": {
        "nct_id": "NCT06449651",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:57.381269",
      "occurred_at": "2026-02-04 10:55:57.381269",
      "payload": {
        "nct_id": "NCT06807424",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:57.366483",
      "occurred_at": "2026-02-04 10:55:57.366483",
      "payload": {
        "nct_id": "NCT06878404",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.139922",
      "occurred_at": "2026-02-04 10:55:56.139922",
      "payload": {
        "nct_id": "NCT03767075",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.116960",
      "occurred_at": "2026-02-04 10:55:56.116960",
      "payload": {
        "nct_id": "NCT06632236",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.095258",
      "occurred_at": "2026-02-04 10:55:56.095258",
      "payload": {
        "nct_id": "NCT05117931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.083043",
      "occurred_at": "2026-02-04 10:55:56.083043",
      "payload": {
        "nct_id": "NCT05299125",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.070465",
      "occurred_at": "2026-02-04 10:55:56.070465",
      "payload": {
        "nct_id": "NCT04538664",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.050185",
      "occurred_at": "2026-02-04 10:55:56.050185",
      "payload": {
        "nct_id": "NCT04988295",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.028387",
      "occurred_at": "2026-02-04 10:55:56.028387",
      "payload": {
        "nct_id": "NCT04487080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:56.002470",
      "occurred_at": "2026-02-04 10:55:56.002470",
      "payload": {
        "nct_id": "NCT05663866",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.983392",
      "occurred_at": "2026-02-04 10:55:55.983392",
      "payload": {
        "nct_id": "NCT04077463",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.951714",
      "occurred_at": "2026-02-04 10:55:55.951714",
      "payload": {
        "nct_id": "NCT06662786",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.935454",
      "occurred_at": "2026-02-04 10:55:55.935454",
      "payload": {
        "nct_id": "NCT05488314",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.922805",
      "occurred_at": "2026-02-04 10:55:55.922805",
      "payload": {
        "nct_id": "NCT05498428",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.907248",
      "occurred_at": "2026-02-04 10:55:55.907248",
      "payload": {
        "nct_id": "NCT06532032",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.894923",
      "occurred_at": "2026-02-04 10:55:55.894923",
      "payload": {
        "nct_id": "NCT05908734",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.881943",
      "occurred_at": "2026-02-04 10:55:55.881943",
      "payload": {
        "nct_id": "NCT06667076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.858770",
      "occurred_at": "2026-02-04 10:55:55.858770",
      "payload": {
        "nct_id": "NCT02609776",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.845147",
      "occurred_at": "2026-02-04 10:55:55.845147",
      "payload": {
        "nct_id": "NCT06750094",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.829525",
      "occurred_at": "2026-02-04 10:55:55.829525",
      "payload": {
        "nct_id": "NCT06385080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:55.389430",
      "occurred_at": "2026-02-04 10:55:55.389430",
      "payload": {
        "nct_id": "NCT06649695",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:53.064855",
      "occurred_at": "2026-02-04 10:55:53.064855",
      "payload": {
        "nct_id": "NCT06852222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:53.049450",
      "occurred_at": "2026-02-04 10:55:53.049450",
      "payload": {
        "nct_id": "NCT04811560",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:53.035478",
      "occurred_at": "2026-02-04 10:55:53.035478",
      "payload": {
        "nct_id": "NCT07295951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:53.023292",
      "occurred_at": "2026-02-04 10:55:53.023292",
      "payload": {
        "nct_id": "NCT05453903",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:52.194427",
      "occurred_at": "2026-02-04 10:55:52.194427",
      "payload": {
        "nct_id": "NCT07164443",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:52.180450",
      "occurred_at": "2026-02-04 10:55:52.180450",
      "payload": {
        "nct_id": "NCT07225946",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:52.159238",
      "occurred_at": "2026-02-04 10:55:52.159238",
      "payload": {
        "nct_id": "NCT07319871",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:51.075020",
      "occurred_at": "2026-02-04 10:55:51.075020",
      "payload": {
        "nct_id": "NCT07276399",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:51.061386",
      "occurred_at": "2026-02-04 10:55:51.061386",
      "payload": {
        "nct_id": "NCT05379595",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:51.047854",
      "occurred_at": "2026-02-04 10:55:51.047854",
      "payload": {
        "nct_id": "NCT07227025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:50.334857",
      "occurred_at": "2026-02-04 10:55:50.334857",
      "payload": {
        "nct_id": "NCT05601973",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.541449",
      "occurred_at": "2026-02-04 10:55:36.541449",
      "payload": {
        "nct_id": "NCT04656951",
        "title": "Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.531231",
      "occurred_at": "2026-02-04 10:55:36.531231",
      "payload": {
        "nct_id": "NCT05527340",
        "title": "Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients."
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.519741",
      "occurred_at": "2026-02-04 10:55:36.519741",
      "payload": {
        "nct_id": "NCT03289299",
        "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.506028",
      "occurred_at": "2026-02-04 10:55:36.506028",
      "payload": {
        "nct_id": "NCT02925234",
        "title": "A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.090232",
      "occurred_at": "2026-02-04 10:55:36.090232",
      "payload": {
        "nct_id": "NCT05666700",
        "title": "CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.078881",
      "occurred_at": "2026-02-04 10:55:36.078881",
      "payload": {
        "nct_id": "NCT06189833",
        "title": "Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.067517",
      "occurred_at": "2026-02-04 10:55:36.067517",
      "payload": {
        "nct_id": "NCT06149910",
        "title": "Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma That Aim to Achieve and Maintain Measurable Residual Disease (MRD)-Negativity in Community Oncology Settings"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.056196",
      "occurred_at": "2026-02-04 10:55:36.056196",
      "payload": {
        "nct_id": "NCT03188172",
        "title": "MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia."
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.044614",
      "occurred_at": "2026-02-04 10:55:36.044614",
      "payload": {
        "nct_id": "NCT03942224",
        "title": "A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, Bortezomib (VElcade) and Dexamethasone Followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE Study)"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:36.037708",
      "occurred_at": "2026-02-04 10:55:36.037708",
      "payload": {
        "nct_id": "NCT06505369",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:36.019300",
      "occurred_at": "2026-02-04 10:55:36.019300",
      "payload": {
        "nct_id": "NCT04140162",
        "title": "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.566014",
      "occurred_at": "2026-02-04 10:55:35.566014",
      "payload": {
        "nct_id": "NCT03710603",
        "title": "A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.545424",
      "occurred_at": "2026-02-04 10:55:35.545424",
      "payload": {
        "nct_id": "NCT06107738",
        "title": "IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab As Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.534747",
      "occurred_at": "2026-02-04 10:55:35.534747",
      "payload": {
        "nct_id": "NCT04667663",
        "title": "Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.524561",
      "occurred_at": "2026-02-04 10:55:35.524561",
      "payload": {
        "nct_id": "NCT04023747",
        "title": "Oxford Pre-cancerous Lymphoproliferative Disorders: Analysis and Interception Study"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.513988",
      "occurred_at": "2026-02-04 10:55:35.513988",
      "payload": {
        "nct_id": "NCT06549634",
        "title": "Biomarkers of AKI in Patients With Multiple Myeloma Receiving Daratumumab: A Pilot Study"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:35.507380",
      "occurred_at": "2026-02-04 10:55:35.507380",
      "payload": {
        "nct_id": "NCT06100237",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.491083",
      "occurred_at": "2026-02-04 10:55:35.491083",
      "payload": {
        "nct_id": "NCT06142396",
        "title": "Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.480454",
      "occurred_at": "2026-02-04 10:55:35.480454",
      "payload": {
        "nct_id": "NCT05001087",
        "title": "A \"Physician & Patient-powered\" Cohort Registry"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.469308",
      "occurred_at": "2026-02-04 10:55:35.469308",
      "payload": {
        "nct_id": "NCT03236428",
        "title": "A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:35.462453",
      "occurred_at": "2026-02-04 10:55:35.462453",
      "payload": {
        "nct_id": "NCT06477783",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:35.449275",
      "occurred_at": "2026-02-04 10:55:35.449275",
      "payload": {
        "nct_id": "NCT06353022",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:35.436226",
      "occurred_at": "2026-02-04 10:55:35.436226",
      "payload": {
        "nct_id": "NCT05849610",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:35.003470",
      "occurred_at": "2026-02-04 10:55:35.003470",
      "payload": {
        "nct_id": "NCT04166565",
        "title": "Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease. The ANTARES Study"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:34.997270",
      "occurred_at": "2026-02-04 10:55:34.997270",
      "payload": {
        "nct_id": "NCT05469893",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.980490",
      "occurred_at": "2026-02-04 10:55:34.980490",
      "payload": {
        "nct_id": "NCT03556332",
        "title": "Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.960673",
      "occurred_at": "2026-02-04 10:55:34.960673",
      "payload": {
        "nct_id": "NCT04268498",
        "title": "Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.948421",
      "occurred_at": "2026-02-04 10:55:34.948421",
      "payload": {
        "nct_id": "NCT07032714",
        "title": "MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.937270",
      "occurred_at": "2026-02-04 10:55:34.937270",
      "payload": {
        "nct_id": "NCT04775550",
        "title": "B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.480995",
      "occurred_at": "2026-02-04 10:55:34.480995",
      "payload": {
        "nct_id": "NCT04052880",
        "title": "A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:34.473611",
      "occurred_at": "2026-02-04 10:55:34.473611",
      "payload": {
        "nct_id": "NCT07107529",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.456990",
      "occurred_at": "2026-02-04 10:55:34.456990",
      "payload": {
        "nct_id": "NCT06348108",
        "title": "A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.446188",
      "occurred_at": "2026-02-04 10:55:34.446188",
      "payload": {
        "nct_id": "NCT03314181",
        "title": "A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:34.435355",
      "occurred_at": "2026-02-04 10:55:34.435355",
      "payload": {
        "nct_id": "NCT06461988",
        "title": "An Open-Label, Non-Randomized, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:34.428914",
      "occurred_at": "2026-02-04 10:55:34.428914",
      "payload": {
        "nct_id": "NCT06993675",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.965662",
      "occurred_at": "2026-02-04 10:55:33.965662",
      "payload": {
        "nct_id": "NCT03004287",
        "title": "2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.946326",
      "occurred_at": "2026-02-04 10:55:33.946326",
      "payload": {
        "nct_id": "NCT04497961",
        "title": "Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.935798",
      "occurred_at": "2026-02-04 10:55:33.935798",
      "payload": {
        "nct_id": "NCT04071457",
        "title": "S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:33.913810",
      "occurred_at": "2026-02-04 10:55:33.913810",
      "payload": {
        "nct_id": "NCT05572229",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.896171",
      "occurred_at": "2026-02-04 10:55:33.896171",
      "payload": {
        "nct_id": "NCT04302324",
        "title": "A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.885930",
      "occurred_at": "2026-02-04 10:55:33.885930",
      "payload": {
        "nct_id": "NCT03500445",
        "title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.875211",
      "occurred_at": "2026-02-04 10:55:33.875211",
      "payload": {
        "nct_id": "NCT04176718",
        "title": "A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.863595",
      "occurred_at": "2026-02-04 10:55:33.863595",
      "payload": {
        "nct_id": "NCT03315026",
        "title": "Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:33.403147",
      "occurred_at": "2026-02-04 10:55:33.403147",
      "payload": {
        "nct_id": "NCT07110844",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.386260",
      "occurred_at": "2026-02-04 10:55:33.386260",
      "payload": {
        "nct_id": "NCT06237803",
        "title": "EMN Prospective Sample Collection Project"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.375070",
      "occurred_at": "2026-02-04 10:55:33.375070",
      "payload": {
        "nct_id": "NCT06472778",
        "title": "Smoldering Pathway Assessment Real-World Knowledge (SPARK) Study-Retrospective Observational, Non-interventional Chart Review Study in Smoldering Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:33.368395",
      "occurred_at": "2026-02-04 10:55:33.368395",
      "payload": {
        "nct_id": "NCT07258511",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.349280",
      "occurred_at": "2026-02-04 10:55:33.349280",
      "payload": {
        "nct_id": "NCT03290950",
        "title": "Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:33.338414",
      "occurred_at": "2026-02-04 10:55:33.338414",
      "payload": {
        "nct_id": "NCT04009109",
        "title": "A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.811225",
      "occurred_at": "2026-02-04 10:55:32.811225",
      "payload": {
        "nct_id": "NCT04151667",
        "title": "Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.797997",
      "occurred_at": "2026-02-04 10:55:32.797997",
      "payload": {
        "nct_id": "NCT05243797",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.780753",
      "occurred_at": "2026-02-04 10:55:32.780753",
      "payload": {
        "nct_id": "NCT07030517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.758791",
      "occurred_at": "2026-02-04 10:55:32.758791",
      "payload": {
        "nct_id": "NCT07105059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.745417",
      "occurred_at": "2026-02-04 10:55:32.745417",
      "payload": {
        "nct_id": "NCT06577025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.720685",
      "occurred_at": "2026-02-04 10:55:32.720685",
      "payload": {
        "nct_id": "NCT04696809",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.704037",
      "occurred_at": "2026-02-04 10:55:32.704037",
      "payload": {
        "nct_id": "NCT06768489",
        "title": "A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.697909",
      "occurred_at": "2026-02-04 10:55:32.697909",
      "payload": {
        "nct_id": "NCT06425991",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.681980",
      "occurred_at": "2026-02-04 10:55:32.681980",
      "payload": {
        "nct_id": "NCT06604715",
        "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.671815",
      "occurred_at": "2026-02-04 10:55:32.671815",
      "payload": {
        "nct_id": "NCT05652335",
        "title": "Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.631005",
      "occurred_at": "2026-02-04 10:55:32.631005",
      "payload": {
        "nct_id": "NCT05572515",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.599847",
      "occurred_at": "2026-02-04 10:55:32.599847",
      "payload": {
        "nct_id": "NCT05455320",
        "title": "A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.577308",
      "occurred_at": "2026-02-04 10:55:32.577308",
      "payload": {
        "nct_id": "NCT07266441",
        "title": "A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.115169",
      "occurred_at": "2026-02-04 10:55:32.115169",
      "payload": {
        "nct_id": "NCT04586426",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.101569",
      "occurred_at": "2026-02-04 10:55:32.101569",
      "payload": {
        "nct_id": "NCT05552222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.081277",
      "occurred_at": "2026-02-04 10:55:32.081277",
      "payload": {
        "nct_id": "NCT05050097",
        "title": "A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.061170",
      "occurred_at": "2026-02-04 10:55:32.061170",
      "payload": {
        "nct_id": "NCT06500884",
        "title": "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.052964",
      "occurred_at": "2026-02-04 10:55:32.052964",
      "payload": {
        "nct_id": "NCT05338775",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:32.035863",
      "occurred_at": "2026-02-04 10:55:32.035863",
      "payload": {
        "nct_id": "NCT04634552",
        "title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.028592",
      "occurred_at": "2026-02-04 10:55:32.028592",
      "payload": {
        "nct_id": "NCT04722146",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:32.016244",
      "occurred_at": "2026-02-04 10:55:32.016244",
      "payload": {
        "nct_id": "NCT05083169",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:31.996941",
      "occurred_at": "2026-02-04 10:55:31.996941",
      "payload": {
        "nct_id": "NCT05160584",
        "title": "A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:31.980247",
      "occurred_at": "2026-02-04 10:55:31.980247",
      "payload": {
        "nct_id": "NCT04108195",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:31.963602",
      "occurred_at": "2026-02-04 10:55:31.963602",
      "payload": {
        "nct_id": "NCT03399799",
        "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:31.952909",
      "occurred_at": "2026-02-04 10:55:31.952909",
      "payload": {
        "nct_id": "NCT04933539",
        "title": "A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:31.942213",
      "occurred_at": "2026-02-04 10:55:31.942213",
      "payload": {
        "nct_id": "NCT03652064",
        "title": "A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:31.931968",
      "occurred_at": "2026-02-04 10:55:31.931968",
      "payload": {
        "nct_id": "NCT04557098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:31.884620",
      "occurred_at": "2026-02-04 10:55:31.884620",
      "payload": {
        "nct_id": "NCT04113018",
        "title": "LCI-HEM-MYE-KRdD-001: Phase II Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:31.870335",
      "occurred_at": "2026-02-04 10:55:31.870335",
      "payload": {
        "nct_id": "NCT06066346",
        "title": "Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.873271",
      "occurred_at": "2026-02-04 10:55:28.873271",
      "payload": {
        "nct_id": "NCT05858632",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.859364",
      "occurred_at": "2026-02-04 10:55:28.859364",
      "payload": {
        "nct_id": "NCT04645355",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.847534",
      "occurred_at": "2026-02-04 10:55:28.847534",
      "payload": {
        "nct_id": "NCT06563323",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.835437",
      "occurred_at": "2026-02-04 10:55:28.835437",
      "payload": {
        "nct_id": "NCT06586281",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.823756",
      "occurred_at": "2026-02-04 10:55:28.823756",
      "payload": {
        "nct_id": "NCT05004727",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.811317",
      "occurred_at": "2026-02-04 10:55:28.811317",
      "payload": {
        "nct_id": "NCT05669833",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.789689",
      "occurred_at": "2026-02-04 10:55:28.789689",
      "payload": {
        "nct_id": "NCT06651489",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.778362",
      "occurred_at": "2026-02-04 10:55:28.778362",
      "payload": {
        "nct_id": "NCT04882098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.763359",
      "occurred_at": "2026-02-04 10:55:28.763359",
      "payload": {
        "nct_id": "NCT04936308",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.746422",
      "occurred_at": "2026-02-04 10:55:28.746422",
      "payload": {
        "nct_id": "NCT04929210",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.731885",
      "occurred_at": "2026-02-04 10:55:28.731885",
      "payload": {
        "nct_id": "NCT06408935",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.719087",
      "occurred_at": "2026-02-04 10:55:28.719087",
      "payload": {
        "nct_id": "NCT05049798",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.697322",
      "occurred_at": "2026-02-04 10:55:28.697322",
      "payload": {
        "nct_id": "NCT07141004",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.685354",
      "occurred_at": "2026-02-04 10:55:28.685354",
      "payload": {
        "nct_id": "NCT05347095",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.671257",
      "occurred_at": "2026-02-04 10:55:28.671257",
      "payload": {
        "nct_id": "NCT06663332",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.659267",
      "occurred_at": "2026-02-04 10:55:28.659267",
      "payload": {
        "nct_id": "NCT03451851",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.223418",
      "occurred_at": "2026-02-04 10:55:28.223418",
      "payload": {
        "nct_id": "NCT04496063",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.210078",
      "occurred_at": "2026-02-04 10:55:28.210078",
      "payload": {
        "nct_id": "NCT05387031",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.188100",
      "occurred_at": "2026-02-04 10:55:28.188100",
      "payload": {
        "nct_id": "NCT02103361",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.175181",
      "occurred_at": "2026-02-04 10:55:28.175181",
      "payload": {
        "nct_id": "NCT05299931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.163268",
      "occurred_at": "2026-02-04 10:55:28.163268",
      "payload": {
        "nct_id": "NCT03941132",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.150797",
      "occurred_at": "2026-02-04 10:55:28.150797",
      "payload": {
        "nct_id": "NCT06807593",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.139481",
      "occurred_at": "2026-02-04 10:55:28.139481",
      "payload": {
        "nct_id": "NCT05083182",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.110143",
      "occurred_at": "2026-02-04 10:55:28.110143",
      "payload": {
        "nct_id": "NCT04372108",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:28.083576",
      "occurred_at": "2026-02-04 10:55:28.083576",
      "payload": {
        "nct_id": "NCT05092269",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.621294",
      "occurred_at": "2026-02-04 10:55:27.621294",
      "payload": {
        "nct_id": "NCT03899077",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.606596",
      "occurred_at": "2026-02-04 10:55:27.606596",
      "payload": {
        "nct_id": "NCT03141671",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.573303",
      "occurred_at": "2026-02-04 10:55:27.573303",
      "payload": {
        "nct_id": "NCT03902951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.559153",
      "occurred_at": "2026-02-04 10:55:27.559153",
      "payload": {
        "nct_id": "NCT03903835",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.543841",
      "occurred_at": "2026-02-04 10:55:27.543841",
      "payload": {
        "nct_id": "NCT02913196",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.519096",
      "occurred_at": "2026-02-04 10:55:27.519096",
      "payload": {
        "nct_id": "NCT06067269",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.504634",
      "occurred_at": "2026-02-04 10:55:27.504634",
      "payload": {
        "nct_id": "NCT04181203",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.482111",
      "occurred_at": "2026-02-04 10:55:27.482111",
      "payload": {
        "nct_id": "NCT06274047",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.468952",
      "occurred_at": "2026-02-04 10:55:27.468952",
      "payload": {
        "nct_id": "NCT05960578",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.454155",
      "occurred_at": "2026-02-04 10:55:27.454155",
      "payload": {
        "nct_id": "NCT07002320",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.439854",
      "occurred_at": "2026-02-04 10:55:27.439854",
      "payload": {
        "nct_id": "NCT04662580",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.425334",
      "occurred_at": "2026-02-04 10:55:27.425334",
      "payload": {
        "nct_id": "NCT04325828",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.410466",
      "occurred_at": "2026-02-04 10:55:27.410466",
      "payload": {
        "nct_id": "NCT04108208",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.393912",
      "occurred_at": "2026-02-04 10:55:27.393912",
      "payload": {
        "nct_id": "NCT05884398",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.378414",
      "occurred_at": "2026-02-04 10:55:27.378414",
      "payload": {
        "nct_id": "NCT04557059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.363480",
      "occurred_at": "2026-02-04 10:55:27.363480",
      "payload": {
        "nct_id": "NCT03523442",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.349821",
      "occurred_at": "2026-02-04 10:55:27.349821",
      "payload": {
        "nct_id": "NCT05901649",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.336398",
      "occurred_at": "2026-02-04 10:55:27.336398",
      "payload": {
        "nct_id": "NCT03767244",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.320088",
      "occurred_at": "2026-02-04 10:55:27.320088",
      "payload": {
        "nct_id": "NCT05818683",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:27.305739",
      "occurred_at": "2026-02-04 10:55:27.305739",
      "payload": {
        "nct_id": "NCT04267887",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:25.958334",
      "occurred_at": "2026-02-04 10:55:25.958334",
      "payload": {
        "nct_id": "NCT06358638",
        "title": "Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodY"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:24.636201",
      "occurred_at": "2026-02-04 10:55:24.636201",
      "payload": {
        "nct_id": "NCT04951622",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:23.288619",
      "occurred_at": "2026-02-04 10:55:23.288619",
      "payload": {
        "nct_id": "NCT05265273",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:23.273759",
      "occurred_at": "2026-02-04 10:55:23.273759",
      "payload": {
        "nct_id": "NCT06251076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:20.960466",
      "occurred_at": "2026-02-04 10:55:20.960466",
      "payload": {
        "nct_id": "NCT06143878",
        "title": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:20.517599",
      "occurred_at": "2026-02-04 10:55:20.517599",
      "payload": {
        "nct_id": "NCT07217587",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:20.061651",
      "occurred_at": "2026-02-04 10:55:20.061651",
      "payload": {
        "nct_id": "NCT07196722",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:20.041066",
      "occurred_at": "2026-02-04 10:55:20.041066",
      "payload": {
        "nct_id": "NCT06881251",
        "title": "A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants With Moderate to Severe AD"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:20.029710",
      "occurred_at": "2026-02-04 10:55:20.029710",
      "payload": {
        "nct_id": "NCT07258485",
        "title": "A Study to Evaluate Sleep Electroencephalogram (EEG) Features in Participants With Major Depressive Disorder (MDD)"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:20.023181",
      "occurred_at": "2026-02-04 10:55:20.023181",
      "payload": {
        "nct_id": "NCT05923073",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:20.005537",
      "occurred_at": "2026-02-04 10:55:20.005537",
      "payload": {
        "nct_id": "NCT06095115",
        "title": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.979189",
      "occurred_at": "2026-02-04 10:55:19.979189",
      "payload": {
        "nct_id": "NCT06934226",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.964990",
      "occurred_at": "2026-02-04 10:55:19.964990",
      "payload": {
        "nct_id": "NCT07227454",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:19.945820",
      "occurred_at": "2026-02-04 10:55:19.945820",
      "payload": {
        "nct_id": "NCT07230860",
        "title": "A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.928674",
      "occurred_at": "2026-02-04 10:55:19.928674",
      "payload": {
        "nct_id": "NCT05242471",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.909415",
      "occurred_at": "2026-02-04 10:55:19.909415",
      "payload": {
        "nct_id": "NCT07196748",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:19.891011",
      "occurred_at": "2026-02-04 10:55:19.891011",
      "payload": {
        "nct_id": "NCT06785012",
        "title": "A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants With Major Depressive Disorder (MDD)"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.884059",
      "occurred_at": "2026-02-04 10:55:19.884059",
      "payload": {
        "nct_id": "NCT06741969",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:19.864642",
      "occurred_at": "2026-02-04 10:55:19.864642",
      "payload": {
        "nct_id": "NCT05841030",
        "title": "A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNRI"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.857162",
      "occurred_at": "2026-02-04 10:55:19.857162",
      "payload": {
        "nct_id": "NCT05242484",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.838650",
      "occurred_at": "2026-02-04 10:55:19.838650",
      "payload": {
        "nct_id": "NCT03218488",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.817134",
      "occurred_at": "2026-02-04 10:55:19.817134",
      "payload": {
        "nct_id": "NCT05912517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:19.803926",
      "occurred_at": "2026-02-04 10:55:19.803926",
      "payload": {
        "nct_id": "NCT06559306",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 10:55:19.337764",
      "occurred_at": "2026-02-04 10:55:19.337764",
      "payload": {
        "nct_id": "NCT06220604",
        "title": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:17.955571",
      "occurred_at": "2026-02-04 10:55:17.955571",
      "payload": {
        "nct_id": "NCT04033445",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:17.918145",
      "occurred_at": "2026-02-04 10:55:17.918145",
      "payload": {
        "nct_id": "NCT03466411",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:08.680826",
      "occurred_at": "2026-02-04 10:55:08.680826",
      "payload": {
        "nct_id": "NCT06208150",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:08.663940",
      "occurred_at": "2026-02-04 10:55:08.663940",
      "payload": {
        "nct_id": "NCT06285318",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 10:55:08.647337",
      "occurred_at": "2026-02-04 10:55:08.647337",
      "payload": {
        "nct_id": "NCT05972135",
        "linked_assets": 1
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": "2026-02-04 10:55:05.508786",
      "occurred_at": "2026-02-04 10:55:05.508786",
      "payload": {
        "as_of_date": null,
        "pdf_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-Pipeline-4Q25.pdf",
        "assets_seen": 40
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.506786",
      "occurred_at": "2026-02-04 10:55:05.506786",
      "payload": {
        "asset": "Leprosy",
        "indication": "under review by regulatory bodies.",
        "stage": "Phase 3",
        "therapeutic_area": null
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.498290",
      "occurred_at": "2026-02-04 10:55:05.498290",
      "payload": {
        "asset": "actorXla",
        "indication": "i o n",
        "stage": "Phase 2",
        "therapeutic_area": null
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.477598",
      "occurred_at": "2026-02-04 10:55:05.477598",
      "payload": {
        "asset": "JNJ-1887 sCD59",
        "indication": "Geographic Atrophy",
        "stage": "Phase 3",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.468386",
      "occurred_at": "2026-02-04 10:55:05.468386",
      "payload": {
        "asset": "Gravis",
        "indication": "Indications for Major Depressive Disorder",
        "stage": "Phase 2",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.454973",
      "occurred_at": "2026-02-04 10:55:05.454973",
      "payload": {
        "asset": "JNJ-5120",
        "indication": "Major Depressive",
        "stage": "Phase 1",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.421745",
      "occurred_at": "2026-02-04 10:55:05.421745",
      "payload": {
        "asset": "nipocalimab",
        "indication": "Chronic Inflammatory",
        "stage": "Phase 3",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.417052",
      "occurred_at": "2026-02-04 10:55:05.417052",
      "payload": {
        "asset": "nipocalimab",
        "indication": "Hemolytic Disease",
        "stage": "Phase 1",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.414776",
      "occurred_at": "2026-02-04 10:55:05.414776",
      "payload": {
        "asset": "nipocalimab",
        "indication": "Fetal and Neonatal",
        "stage": "Phase 3",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 10:55:05.412504",
      "occurred_at": "2026-02-04 10:55:05.412504",
      "payload": {
        "asset": "nipocalimab",
        "indication": "Warm Autoimmune",
        "stage": "Phase 3",
        "therapeutic_area": "Immunology"
      }
    }
  ],
  "trials": [
    {
      "nct_id": "NCT04113018",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-03",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06066346",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-03",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05388669",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03390504",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03462719",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03901963",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06266663",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03596645",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03451851",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04033445",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT03466411",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "STELARA",
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT03301220",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-30",
      "linked_assets": []
    },
    {
      "nct_id": "NCT02365597",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-30",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03881098",
      "overall_status": "RECRUITING",
      "phase": "NA",
      "last_update_posted": "2026-01-29",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06319820",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-27",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04557098",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-27",
      "linked_assets": [
        "TECVAYLI"
      ]
    },
    {
      "nct_id": "NCT05421663",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-27",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05289687",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-26",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06193863",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-23",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07245394",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-23",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05316155",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-22",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05601973",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-21",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05900388",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-21",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04933539",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03652064",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06220604",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04267887",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": [
        "ERLEADA"
      ]
    },
    {
      "nct_id": "NCT05972135",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": [
        "TECVAYLI"
      ]
    },
    {
      "nct_id": "NCT06768489",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06604715",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05652335",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05455320",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07266441",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05050097",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06500884",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04634552",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05160584",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03399799",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06881251",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07258485",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06095115",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07230860",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06785012",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05841030",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06919965",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06533098",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "nipocalimab"
      ]
    },
    {
      "nct_id": "NCT05379634",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "nipocalimab"
      ]
    },
    {
      "nct_id": "NCT06449651",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "nipocalimab"
      ]
    },
    {
      "nct_id": "NCT06741969",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "nipocalimab"
      ]
    },
    {
      "nct_id": "NCT05327114",
      "overall_status": "RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "nipocalimab"
      ]
    }
  ]
}